$569.75 Million in Sales Expected for Incyte Co. (NASDAQ:INCY) This Quarter

Wall Street analysts expect Incyte Co. (NASDAQ:INCY) to post $569.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Incyte’s earnings. The highest sales estimate is $593.98 million and the lowest is $559.00 million. Incyte reported sales of $468.40 million during the same quarter last year, which indicates a positive year over year growth rate of 21.6%. The company is scheduled to announce its next quarterly earnings results on Thursday, February 13th.

On average, analysts expect that Incyte will report full year sales of $2.14 billion for the current financial year, with estimates ranging from $2.07 billion to $2.18 billion. For the next fiscal year, analysts forecast that the company will post sales of $2.47 billion, with estimates ranging from $2.38 billion to $2.64 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Incyte.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.27. Incyte had a return on equity of 20.07% and a net margin of 19.21%. The company had revenue of $551.58 million for the quarter, compared to analysts’ expectations of $534.73 million. During the same period in the previous year, the firm earned $0.41 EPS. The firm’s revenue was up 22.7% compared to the same quarter last year.

INCY has been the topic of several recent research reports. Nomura increased their price target on Incyte from $100.00 to $111.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Mizuho restated a “buy” rating and set a $95.00 price target on shares of Incyte in a report on Tuesday, October 29th. Morgan Stanley increased their price target on Incyte from $82.00 to $87.00 and gave the company an “equal weight” rating in a report on Thursday, September 5th. Leerink Swann set a $90.00 price objective on Incyte and gave the company a “hold” rating in a research report on Wednesday, July 31st. Finally, Cowen reaffirmed a “buy” rating on shares of Incyte in a research report on Friday, September 27th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $92.90.

In other news, EVP Paula J. Swain sold 2,500 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $80.00, for a total transaction of $200,000.00. Following the transaction, the executive vice president now owns 44,112 shares of the company’s stock, valued at approximately $3,528,960. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Wendy L. Dixon sold 10,576 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $84.16, for a total value of $890,076.16. Following the transaction, the director now directly owns 22,916 shares in the company, valued at approximately $1,928,610.56. The disclosure for this sale can be found here. Insiders sold a total of 91,794 shares of company stock worth $7,646,955 in the last ninety days. 17.10% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Commonwealth Bank of Australia grew its position in shares of Incyte by 49.2% during the 2nd quarter. Commonwealth Bank of Australia now owns 376 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 124 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Incyte by 617.7% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 445 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 383 shares during the last quarter. Pathstone Family Office LLC purchased a new stake in Incyte in the second quarter valued at about $34,000. Captrust Financial Advisors purchased a new stake in Incyte in the second quarter valued at about $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Incyte in the third quarter valued at about $46,000. 91.58% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ INCY traded up $0.91 during trading hours on Thursday, reaching $86.70. The company’s stock had a trading volume of 1,235,100 shares, compared to its average volume of 978,750. The firm’s 50-day moving average price is $79.08 and its 200-day moving average price is $80.57. Incyte has a 1 year low of $57.00 and a 1 year high of $89.30. The company has a market capitalization of $18.48 billion, a price-to-earnings ratio of 105.73, a PEG ratio of 1.25 and a beta of 0.99. The company has a quick ratio of 5.01, a current ratio of 5.02 and a debt-to-equity ratio of 0.02.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

See Also: Understanding Market Liquidity

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.